Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Gene Therapy for Prostate Cancer: A Review

Author(s): Swapnil S. Talkar and Vandana B. Patravale*

Volume 21, Issue 3, 2021

Published on: 31 May, 2020

Page: [385 - 396] Pages: 12

DOI: 10.2174/1871530320666200531141455

Price: $65

Abstract

Background: According to the American Cancer Society, prostate cancer ranks second in terms of mortality and is a front-runner of newly detected cases. Conventional therapies neither eradicated cancer nor increased the life expectancy of patients obviating the need for less toxic as well as efficient therapies to treat cancer. Gene therapy alone, or in combination with conventional therapies, possesses a strong potential to combat cancer.

Methods: This review encompasses a brief note on the etiology and conventional therapy of prostate cancer with an emphasis on gene therapy and its suitability for the treatment of prostate cancer.

Results: A comprehensive range of gene therapy approaches have been successfully explored for prostate cancer treatment in animal models and this has been well translated into early clinical trials. We have also discussed in brief about specific therapeutic genes and suitable vector systems for gene therapy in prostate cancer.

Conclusion: Based on the results of these clinical trials, the application of gene therapy in prostate cancer therapeutics can be satisfactorily established.

Keywords: Prostate cancer, gene therapy, clinical trials, viral, vectors, non-viral vectors, review.

Next »
Graphical Abstract

[1]
Key Statistics for Prostate Cancer | Prostate Cancer Facts. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html (Accessed Aug 1, 2019)
[2]
Clark, J.; Edwards, S.; Feber, A.; Flohr, P.; John, M.; Giddings, I.; Crossland, S.; Stratton, M.R.; Wooster, R.; Campbell, C.; Cooper, C.S. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene, 2003, 22(8), 1247-1252.
[http://dx.doi.org/10.1038/sj.onc.1206247] [PMID: 12606952]
[3]
Varambally, S.; Dhanasekaran, S.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419(6907), 624-629.
[http://dx.doi.org/10.1038/nature01075] [PMID: 12374981]
[4]
Jalava, S.E.; Porkka, K.P.; Rauhala, H.E.; Isotalo, J.; Tammela, T.L.; Visakorpi, T. TCEB1 promotes invasion of prostate cancer cells. Int. J. Cancer, 2009, 124(1), 95-102.
[http://dx.doi.org/10.1002/ijc.23916] [PMID: 18844214]
[5]
Saramäki, O.; Willi, N.; Bratt, O.; Gasser, T.C.; Koivisto, P.; Nupponen, N.N.; Bubendorf, L.; Visakorpi, T. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am. J. Pathol., 2001, 159(6), 2089-2094.
[http://dx.doi.org/10.1016/S0002-9440(10)63060-X] [PMID: 11733359]
[6]
Bismar, T.A.; Yoshimoto, M.; Vollmer, R.T.; Duan, Q.; Firszt, M.; Corcos, J.; Squire, J.A. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int., 2011, 107(3), 477-485.
[http://dx.doi.org/10.1111/j.1464-410X.2010.09470.x] [PMID: 20590547]
[7]
Koh, C.M.; Bieberich, C.J.; Dang, C.V.; Nelson, W.G.; Yegnasubramanian, S.; Marzo, A.M. De, MYC and Prostate Cancer. Genes & Cancer, 2010, 1(6), 617-628.
[http://dx.doi.org/10.1177/1947601910379132]
[8]
Cai, C.; He, H.H.; Chen, S.; Coleman, I.; Wang, H.; Fang, Z.; Chen, S.; Nelson, P.S.; Liu, X.S.; Brown, M.; Balk, S.P. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell, 2011, 20(4), 457-471.
[http://dx.doi.org/10.1016/j.ccr.2011.09.001] [PMID: 22014572]
[9]
Castro, E.; Eeles, R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J. Androl., 2012, 14(3), 409-414.
[http://dx.doi.org/10.1038/aja.2011.150]
[10]
Foley, R.; Lawler, M.; Hollywood, D. Reviews gene-based therapy in prostate cancer. Lancet Oncol., 2004, 5(8), 469-479.
[http://dx.doi.org/10.1016/S1470-2045(04)01525-6]]
[11]
Mali, S. Delivery systems for gene therapy. Indian J. Hum. Genet., 2013, 19(1), 3-8.
[http://dx.doi.org/10.4103/0971-6866.112870] [PMID: 23901186]
[12]
Nayerossadat, N.; Maedeh, T.; Ali, P.A. Viral and nonviral delivery systems for gene delivery. Adv. Biomed. Res., 2012, 1, 27.
[http://dx.doi.org/10.4103/2277-9175.98152] [PMID: 23210086]
[13]
Herman, J.R.; Adler, H.L.; Aguilar-Cordova, E.; Rojas-Martinez, A.; Woo, S.; Timme, T.L.; Wheeler, T.M.; Thompson, T.C.; Scardino, P.T. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther., 1999, 10(7), 1239-1249.
[http://dx.doi.org/10.1089/10430349950018229] [PMID: 10340555]
[14]
Thomas, D.; Mazhar, D.; Waxman, J. Mini-review on what is termed gene therapy for prostate cancer., 2004, 465-469.
[http://dx.doi.org/10.1111/j.1464-410X.2004.04652.x]
[15]
Hellebrand, E.; Mautner, J.; Reisbach, G.; Nimmerjahn, F.; Hallek, M.; Mocikat, R.; Hammerschmidt, W. Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Ther., 2006, 13(2), 150-162.
[http://dx.doi.org/10.1038/sj.gt.3302602] [PMID: 16136164]
[16]
Ramamoorth, M.; Narvekar, A. Non viral vectors in gene therapy- an overview. J. Clin. Diagn. Res., 2015, 9(1), GE01-GE06.
[http://dx.doi.org/10.7860/JCDR/2015/10443.5394] [PMID: 25738007]
[17]
Nomikou, N.; Feichtinger, G.A.; Saha, S.; Nuernberger, S.; Heimel, P.; Redl, H.; McHale, A.P. Ultrasound-responsive gene-activated matrices for osteogenic gene therapy using matrix-assisted sonoporation. J. Tissue Eng. Regen. Med., 2018, 12(1), e250-e260.
[http://dx.doi.org/10.1002/term.2406] [PMID: 28084018]
[18]
Gehl, J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand., 2003, 177(4), 437-447.
[http://dx.doi.org/10.1046/j.1365-201X.2003.01093.x] [PMID: 12648161]
[19]
Yao, C.P.; Zhang, Z.X.; Rahmanzadeh, R.; Huettmann, G. Laser-based gene transfection and gene therapy. IEEE Trans. Nanobioscience, 2008, 7(2), 111-119.
[http://dx.doi.org/10.1109/TNB.2008.2000742] [PMID: 18556259]
[20]
Chen, C-B.; Chen, J-Y.; Lee, W-C. Fast transfection of mammalian cells using superparamagnetic nanoparticles under strong magnetic field. J. Nanosci. Nanotechnol., 2009, 9(4), 2651-2659.
[http://dx.doi.org/10.1166/jnn.2009.449] [PMID: 19438016]
[21]
Li, S.D.; Huang, L. Non-viral is superior to viral gene delivery. J. Control. Release, 2007, 123(3), 181-183.
[http://dx.doi.org/10.1016/j.jconrel.2007.09.004] [PMID: 17935817]
[22]
Pissuwan, D.; Niidome, T.; Cortie, M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J. Control. Release, 2011, 149(1), 65-71.
[http://dx.doi.org/10.1016/j.jconrel.2009.12.006] [PMID: 20004222]
[23]
Tros de Ilarduya, C.; Sun, Y.; Düzgüneş, N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci., 2010, 40(3), 159-170.
[http://dx.doi.org/10.1016/j.ejps.2010.03.019] [PMID: 20359532]
[24]
Du, Z.; Munye, M.M.; Tagalakis, A.D.; Manunta, M.D.I.; Hart, S.L. The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations. Sci. Rep., 2014, 4, 7107.
[http://dx.doi.org/10.1038/srep07107] [PMID: 25407686]
[25]
Yano, J.; Hirabayashi, K.; Nakagawa, S.; Yamaguchi, T.; Nogawa, M.; Kashimori, I.; Naito, H.; Kitagawa, H.; Ishiyama, K.; Ohgi, T.; Irimura, T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res., 2004, 10(22), 7721-7726.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-1049] [PMID: 15570006]
[26]
Boussif, O.; Lezoualc’h, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA, 1995, 92(16), 7297-7301.
[http://dx.doi.org/10.1073/pnas.92.16.7297] [PMID: 7638184]
[27]
Ward, C.M.; Read, M.L.; Seymour, L.W. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood, 2001, 97(8), 2221-2229.
[http://dx.doi.org/10.1182/blood.V97.8.2221] [PMID: 11290582]
[28]
Katas, H.; Alpar, H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release, 2006, 115(2), 216-225.
[http://dx.doi.org/10.1016/j.jconrel.2006.07.021] [PMID: 16959358]
[29]
Morille, M.; Passirani, C.; Vonarbourg, A.; Clavreul, A.; Benoit, J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 2008, 29(24-25), 3477-3496.
[http://dx.doi.org/10.1016/j.biomaterials.2008.04.036] [PMID: 18499247]
[30]
Ahmad, A.; Khan, S.; Sakabe, I. S. A. M. U. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer., 2005, 26(4), 1087-1091.
[PMID: 15754006]
[31]
Freytag, S.O.; Movsas, B.; Aref, I.; Stricker, H.; Peabody, J.; Pegg, J.; Zhang, Y.; Barton, K.N.; Brown, S.L.; Lu, M.; Savera, A.; Kim, J.H. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther., 2007, 15(5), 1016-1023.
[http://dx.doi.org/10.1038/mt.sj.6300120] [PMID: 17375076]
[32]
Takamiya, Y.; Short, M.P.; Ezzeddine, Z.D.; Moolten, F.L.; Breakefield, X.O.; Martuza, R.L. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res., 1992, 33(3), 493-503.
[http://dx.doi.org/10.1002/jnr.490330316] [PMID: 1335091]
[33]
Huber, B.E.; Austin, E.A.; Richards, C.A.; Davis, S.T.; Good, S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 1994, 91(17), 8302-8306.
[http://dx.doi.org/10.1073/pnas.91.17.8302] [PMID: 8058798]
[34]
Freytag, S.O.; Stricker, H.; Movsas, B.; Kim, J.H. Prostate cancer gene therapy clinical trials. Mol. Ther., 2007, 15(6), 1042-1052.
[http://dx.doi.org/10.1038/sj.mt.6300162] [PMID: 17406342]
[35]
Kubo, H.; Gardner, T.A.; Wada, Y.; Koeneman, K.S.; Gotoh, A.; Yang, L.; Kao, C.; Lim, S.D.; Amin, M.B.; Yang, H.; Black, M.E.; Matsubara, S.; Nakagawa, M.; Gillenwater, J.Y.; Zhau, H.E.; Chung, L.W. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther., 2003, 14(3), 227-241.
[http://dx.doi.org/10.1089/10430340360535788] [PMID: 12639303]
[36]
Small, E.J.; Carducci, M.A.; Burke, J.M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D.C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther., 2006, 14(1), 107-117.
[http://dx.doi.org/10.1016/j.ymthe.2006.02.011] [PMID: 16690359]
[37]
Simons, J.W.; Mikhak, B.; Chang, J.F.; DeMarzo, A.M.; Carducci, M.A.; Lim, M.; Weber, C.E.; Baccala, A.A.; Goemann, M.A.; Clift, S.M.; Ando, D.G.; Levitsky, H.I.; Cohen, L.K.; Sanda, M.G.; Mulligan, R.C.; Partin, A.W.; Carter, H.B.; Piantadosi, S.; Marshall, F.F.; Nelson, W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res., 1999, 59(20), 5160-5168.
[PMID: 10537292]
[38]
Belldegrun, A.; Tso, C.L.; Zisman, A.; Naitoh, J.; Said, J.; Pantuck, A.J.; Hinkel, A.; deKernion, J.; Figlin, R. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther., 2001, 12(8), 883-892.
[http://dx.doi.org/10.1089/104303401750195854] [PMID: 11387054]
[39]
Small, E.; Higano, C.; Smith, D.; Corman, J.; Centeno, A.; Steidle, C.; Gittelman, M.; Hudes, G.; Sacks, N.; Simons, J. A Phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). J. Clin. Oncol., 2004, 22(14_suppl), 4565-4565.
[40]
DiPaola, R.S.; Plante, M.; Kaufman, H.; Petrylak, D.P.; Israeli, R.; Lattime, E.; Manson, K.; Schuetz, T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl. Med., 2006, 4, 1.
[http://dx.doi.org/10.1186/1479-5876-4-1] [PMID: 16390546]
[41]
Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba, W.J.; Dula, E.; Centeno, A.S.; Nelson, W.G.; Ando, D.; Howard, C.; Borellini, F.; Nguyen, M.; Hege, K.; Simons, J.W. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res., 2007, 13(13), 3883-3891.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-2937] [PMID: 17606721]
[42]
Eder, J.P.; Kantoff, P.W.; Roper, K.; Xu, G.X.; Bubley, G.J.; Boyden, J.; Gritz, L.; Mazzara, G.; Oh, W.K.; Arlen, P.; Tsang, K.Y.; Panicali, D.; Schlom, J.; Kufe, D.W. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res., 2000, 6(5), 1632-1638.
[PMID: 10815880]
[43]
Sanda, M.G.; Smith, D.C.; Charles, L.G.; Hwang, C.; Pienta, K.J.; Schlom, J.; Milenic, D.; Panicali, D.; Montie, J.E. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 1999, 53(2), 260-266.
[http://dx.doi.org/10.1016/S0090-4295(98)00539-1] [PMID: 9933036]
[44]
Gulley, J.; Chen, A.P.; Dahut, W.; Arlen, P.M.; Bastian, A.; Steinberg, S.M.; Tsang, K.; Panicali, D.; Poole, D.; Schlom, J.; Michael, H.J. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate, 2002, 53(2), 109-117.
[http://dx.doi.org/10.1002/pros.10130] [PMID: 12242725]
[45]
Kaufman, H.L.; Wang, W.; Manola, J.; DiPaola, R.S.; Ko, Y-J.; Sweeney, C.; Whiteside, T.L.; Schlom, J.; Wilding, G.; Weiner, L.M.; Phase, I.I. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern cooperative oncology group. J. Clin. Oncol., 2004, 22(11), 2122-2132.
[http://dx.doi.org/10.1200/JCO.2004.08.083] [PMID: 15169798]

Rights & Permissions Print Cite
Article Metrics
43
1
© 2024 Bentham Science Publishers | Privacy Policy